



# Market Announcement

5 May 2023

---

## Nutritional Growth Solutions Ltd (ASX: NGS) – Trading Halt

### Description

The securities of Nutritional Growth Solutions Ltd ('NGS') will be placed in trading halt at the request of NGS, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 9 May 2023 or when the announcement is released to the market.

### Issued by

**Scarlette de Lavaine**

Adviser, Listings Compliance

Sean Maloney  
Australian Securities Exchange  
Level 40, Central Park  
152 – 158 St Georges Terrace  
Perth WA 6000

**By Email:** tradinghaltsperth@asx.com.au

Dear Sean,

**ASX Code: NGS – Trading Halt Request**

Pursuant to ASX Listing Rule 17.1, Nutritional Growth Solutions Limited (ASX:NGS) (**Company**) requests a trading halt of its securities effective immediately.

The trading halt is requested pending the release of an ASX announcement regarding a capital raise.

It is expected the trading halt will end on the earlier of the commencement of normal trading on Tuesday, 9 May 2023, or when an announcement in relation to the capital raise is released to the market.

The Company is not aware of any reason why the trading halt should not be granted and there is no other information to inform the market of in respect of the trading halt.

Yours faithfully



Lee Tamplin  
Local Agent

-ENDS-

*This announcement has been authorised for release by the Board of Directors of Nutritional Growth Solutions Ltd.*

**About Nutritional Growth Solutions**

Nutritional Growth Solutions is a global nutritional health company focused on the well-being of children. NGS develops, produces and sells clinically tested nutritional supplement formulae for children following 20 years of medical research into pediatric nutrition at Schneider Children's Medical Centre, Israel's largest pediatric hospital. The nutritional supplements market has experienced tremendous growth in recent years, but most attention has been focused on adult users and children under three years of age. The three to twelve-year-old consumers represent a larger market opportunity and NGS is highly differentiated from its competitors with clinically tested products and an expanding product portfolio to capture this market opportunity.

[ngsolutions.co](http://ngsolutions.co)